-
1
-
-
0029080640
-
Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes
-
Allen TM, Newman MS, Woodle MC, Mayhew E, Uster PS. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 1995; 62:199-204.
-
(1995)
Int J Cancer
, vol.62
, pp. 199-204
-
-
Allen, T.M.1
Newman, M.S.2
Woodle, M.C.3
Mayhew, E.4
Uster, P.S.5
-
2
-
-
0842279809
-
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors
-
Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85:6949-6953.
-
(1988)
Proc Natl Acad Sci USA
, vol.85
, pp. 6949-6953
-
-
Gabizon, A.1
Papahadjopoulos, D.2
-
3
-
-
0030669086
-
Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors
-
Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs 1997; 54(suppl 4): 15-21.
-
(1997)
Drugs
, vol.54
, Issue.SUPPL. 4
, pp. 15-21
-
-
Gabizon, A.1
Martin, F.2
-
4
-
-
0030579707
-
Doxorubicin in sterically stabilized liposomes
-
Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996; 380:561-562.
-
(1996)
Nature
, vol.380
, pp. 561-562
-
-
Lasic, D.D.1
-
5
-
-
0037334516
-
Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications
-
Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3:319-328.
-
(2003)
Int Immunopharmacol
, vol.3
, pp. 319-328
-
-
Maeda, H.1
Fang, J.2
Inutsuka, T.3
Kitamoto, Y.4
-
6
-
-
0000954203
-
Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomes
-
Lasic DD, Papahadjopoulos D (editors). Amsterdam: Elsevier
-
Mayer LD, Cullis PR, Bally MB. Designing therapeutically optimized liposomal anticancer delivery systems: lessons from conventional liposomes. In: Lasic DD, Papahadjopoulos D (editors): Medical Applications of Liposomes. Amsterdam: Elsevier; 1998, pp. 231-257.
-
(1998)
Medical Applications of Liposomes
, pp. 231-257
-
-
Mayer, L.D.1
Cullis, P.R.2
Bally, M.B.3
-
7
-
-
0026352832
-
Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy
-
Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88:11460-11464.
-
(1991)
Proc Natl Acad Sci USA
, vol.88
, pp. 11460-11464
-
-
Papahadjopoulos, D.1
Allen, T.M.2
Gabizon, A.3
Mayhew, E.4
Matthay, K.5
Huang, S.K.6
-
8
-
-
0027242138
-
Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue
-
Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 1993; 53:3765-3770.
-
(1993)
Cancer Res
, vol.53
, pp. 3765-3770
-
-
Wu, N.Z.1
Da, D.2
Rudoll, T.L.3
Needham, D.4
Whorton, A.R.5
Dewhirst, M.W.6
-
9
-
-
18844475615
-
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group
-
Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, Le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/ CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37:870-877.
-
(2001)
Eur J Cancer
, vol.37
, pp. 870-877
-
-
Judson, I.1
Radford, J.A.2
Harris, M.3
Blay, J.Y.4
Van Hoesel, Q.5
Le Cesne, A.6
-
10
-
-
0031861021
-
Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial
-
Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16:2445-2451.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2445-2451
-
-
Northfelt, D.W.1
Dezube, B.J.2
Thommes, J.A.3
Miller, B.J.4
Fischl, M.A.5
Friedman-Kien, A.6
-
11
-
-
11144357506
-
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
-
O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15:440-449.
-
(2004)
Ann Oncol
, vol.15
, pp. 440-449
-
-
O'Brien, M.E.1
Wigler, N.2
Inbar, M.3
Rosso, R.4
Grischke, E.5
Santoro, A.6
-
12
-
-
0036552104
-
Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer
-
Stebbing J, Gaya A. Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer. Cancer Treat Rev 2002; 28:121-125.
-
(2002)
Cancer Treat Rev
, vol.28
, pp. 121-125
-
-
Stebbing, J.1
Gaya, A.2
-
13
-
-
0032826597
-
Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity
-
Bickels J, Manusama ER, Gutman M, Eggermont AM, Kollender Y, Abu-Abid S, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol 1999; 25:509-514.
-
(1999)
Eur J Surg Oncol
, vol.25
, pp. 509-514
-
-
Bickels, J.1
Manusama, E.R.2
Gutman, M.3
Eggermont, A.M.4
Kollender, Y.5
Abu-Abid, S.6
-
14
-
-
0029738520
-
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial
-
Eggermont AM, Schraffordt KH, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653-2665.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2653-2665
-
-
Eggermont, A.M.1
Schraffordt, K.H.2
Lienard, D.3
Kroon, B.B.4
Van Geel, A.N.5
Hoekstra, H.J.6
-
15
-
-
0009885824
-
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience
-
Eggermont AM, Schraffordt KH, Klausner JM, Kroon BB, Schlag PM, Lienard D, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224:756-764.
-
(1996)
Ann Surg
, vol.224
, pp. 756-764
-
-
Eggermont, A.M.1
Schraffordt, K.H.2
Klausner, J.M.3
Kroon, B.B.4
Schlag, P.M.5
Lienard, D.6
-
16
-
-
0026549021
-
In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion
-
Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992; 16: 234-140.
-
(1992)
World J Surg
, vol.16
, pp. 234-1140
-
-
Lienard, D.1
Lejeune, F.J.2
Ewalenko, P.3
-
17
-
-
0345471470
-
Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: A multicenter study
-
Olieman AF, Lienard D, Eggermont AM, Kroon BB, Lejeune FJ, Hoekstra HJ, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999; 134: 303-407.
-
(1999)
Arch Surg
, vol.134
, pp. 303-407
-
-
Olieman, A.F.1
Lienard, D.2
Eggermont, A.M.3
Kroon, B.B.4
Lejeune, F.J.5
Hoekstra, H.J.6
-
18
-
-
0033952276
-
TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
-
van Der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000; 82:973-980.
-
(2000)
Br J Cancer
, vol.82
, pp. 973-980
-
-
Van Der Veen, A.H.1
De Wilt, J.H.2
Eggermont, A.M.3
Van Tiel, S.T.4
Seynhaeve, A.L.5
Ten Hagen, T.L.6
-
19
-
-
0034012752
-
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
-
de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82:1000-1003.
-
(2000)
Br J Cancer
, vol.82
, pp. 1000-1003
-
-
De Wilt, J.H.1
Ten Hagen, T.L.2
De Boeck, G.3
Van Tiel, S.T.4
De Bruijn, E.A.5
Eggermont, A.M.6
-
20
-
-
0023028369
-
Shock and tissue injury induced by recombinant human cachectin
-
Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470-474.
-
(1986)
Science
, vol.234
, pp. 470-474
-
-
Tracey, K.J.1
Beutler, B.2
Lowry, S.F.3
Merryweather, J.4
Wolpe, S.5
Milsark, I.W.6
-
21
-
-
0023778218
-
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study
-
Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988; 80:1039-1044.
-
(1988)
J Natl Cancer Inst
, vol.80
, pp. 1039-1044
-
-
Spriggs, D.R.1
Sherman, M.L.2
Michie, H.3
Arthur, K.A.4
Imamura, K.5
Wilmore, D.6
-
22
-
-
0033836614
-
Low-dose tumor necrosis factor-alpha augments antiturnor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats
-
ten Hagen TL, van Der Veen AH, Nooijen PT, van Tiel ST, Seynhaeve AL, Eggermont AM. Low-dose tumor necrosis factor-alpha augments antiturnor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 2000; 87:829-837.
-
(2000)
Int J Cancer
, vol.87
, pp. 829-837
-
-
Ten Hagen, T.L.1
Van Der Veen, A.H.2
Nooijen, P.T.3
Van Tiel, S.T.4
Seynhaeve, A.L.5
Eggermont, A.M.6
-
23
-
-
1342288382
-
Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics
-
Brouckaert P, Takahashi N, van Tiel ST, Hostens J, Eggermont AM, Seynhaeve AL, et al. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int J Cancer 2004; 109:442-448.
-
(2004)
Int J Cancer
, vol.109
, pp. 442-448
-
-
Brouckaert, P.1
Takahashi, N.2
Van Tiel, S.T.3
Hostens, J.4
Eggermont, A.M.5
Seynhaeve, A.L.6
-
24
-
-
0024309730
-
Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins
-
Brett J, Gerlach H, Nawroth P, Steinberg S, Godman G, Stern D. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 1989; 169:1977-1991.
-
(1989)
J Exp Med
, vol.169
, pp. 1977-1991
-
-
Brett, J.1
Gerlach, H.2
Nawroth, P.3
Steinberg, S.4
Godman, G.5
Stern, D.6
-
25
-
-
0027053675
-
Influence of extracellular matrix in tumor necrosis factor-induced increase in endothelial permeability
-
Partridge CA, Horvath CJ, Del Vecchio PJ, Phillips PG, Malik AB. Influence of extracellular matrix in tumor necrosis factor-induced increase in endothelial permeability. Am J Physiol 1992; 263:L627-L633.
-
(1992)
Am J Physiol
, vol.263
-
-
Partridge, C.A.1
Horvath, C.J.2
Del Vecchio, P.J.3
Phillips, P.G.4
Malik, A.B.5
-
26
-
-
0029985727
-
Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat
-
Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, Eggermont AM. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 1996; 83:551-555.
-
(1996)
Br J Surg
, vol.83
, pp. 551-555
-
-
Manusama, E.R.1
Nooijen, P.T.2
Stavast, J.3
Durante, N.M.4
Marquet, R.L.5
Eggermont, A.M.6
-
27
-
-
0024470863
-
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice
-
Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 1989; 49: 5922-5930.
-
(1989)
Cancer Res
, vol.49
, pp. 5922-5930
-
-
Mayer, L.D.1
Tai, L.C.2
Ko, D.S.3
Masin, D.4
Ginsberg, R.S.5
Cullis, P.R.6
-
28
-
-
0025341331
-
New colorimetric cytotoxicity assay for anticancer-drug screening
-
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
-
(1990)
J Natl Cancer Inst
, vol.82
, pp. 1107-1112
-
-
Skehan, P.1
Storeng, R.2
Scudiero, D.3
Monks, A.4
McMahon, J.5
Vistica, D.6
-
29
-
-
0025334830
-
Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy
-
Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990; 50:4478-4484.
-
(1990)
Cancer Res
, vol.50
, pp. 4478-4484
-
-
Boucher, Y.1
Baxter, L.T.2
Jain, R.K.3
-
30
-
-
0031903379
-
Transvascular drug delivery in solid tumors
-
Yuan F. Transvascular drug delivery in solid tumors. Semin Radiat Oncol 1998; 8:164-175.
-
(1998)
Semin Radiat Oncol
, vol.8
, pp. 164-175
-
-
Yuan, F.1
-
31
-
-
0023788067
-
Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules
-
Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133:95-109.
-
(1988)
Am J Pathol
, vol.133
, pp. 95-109
-
-
Dvorak, H.F.1
Nagy, J.A.2
Dvorak, J.T.3
Dvorak, A.M.4
-
32
-
-
0033302303
-
Transport of molecules, particles, and cells in solid tumors
-
Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999; 1:241-263.
-
(1999)
Annu Rev Biomed Eng
, vol.1
, pp. 241-263
-
-
Jain, R.K.1
-
33
-
-
0032516078
-
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
-
Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95:4607-4612.
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 4607-4612
-
-
Hobbs, S.K.1
Monsky, W.L.2
Yuan, F.3
Roberts, W.G.4
Griffith, L.5
Torchilin, V.P.6
-
34
-
-
0029150245
-
Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size
-
Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55:3752-3756.
-
(1995)
Cancer Res
, vol.55
, pp. 3752-3756
-
-
Yuan, F.1
Dellian, M.2
Fukumura, D.3
Leunig, M.4
Berk, D.A.5
Torchilin, V.P.6
-
35
-
-
0034835602
-
Liposomal anthracyclines for breast cancer
-
Sparano JA, Winer EP. Liposomal anthracyclines for breast cancer. Semin Oncol 2001; 28:32-40.
-
(2001)
Semin Oncol
, vol.28
, pp. 32-40
-
-
Sparano, J.A.1
Winer, E.P.2
-
36
-
-
0032958135
-
Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice
-
Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999; 43:1-7.
-
(1999)
Cancer Chemother Pharmacol
, vol.43
, pp. 1-7
-
-
Newman, M.S.1
Colbern, G.T.2
Working, P.K.3
Engbers, C.4
Amantea, M.A.5
-
37
-
-
0029963270
-
Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: A new anti-tumour approach
-
Manusama ER, Stavast J, Durante NM, Marquet RL, Eggermont AM. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 1996; 22:152-157.
-
(1996)
Eur J Surg Oncol
, vol.22
, pp. 152-157
-
-
Manusama, E.R.1
Stavast, J.2
Durante, N.M.3
Marquet, R.L.4
Eggermont, A.M.5
|